Stock Scorecard



Stock Summary for Beam Therapeutics Inc (BEAM) - $17.01 as of 6/30/2025 8:00:44 PM EST

Total Score

11 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BEAM

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BEAM

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BEAM

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BEAM

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BEAM (40 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BEAM

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential 6/28/2025 1:10:00 PM
3 Promising Genomics Stocks to Keep an Eye On in 2025 6/27/2025 12:03:00 PM
Cathie Wood Doubles Down On Shopify, Buys The Dip - Dumps $4.6 Million Worth Of Robinhood Stock At Peak - ARK Fintech Innovation ETF ( BATS:ARKF ) , ARK Innovation ETF ( BATS:ARKK ) 6/26/2025 1:23:00 AM
Cathie Wood Drops $6.5 Million On SHOP And ABNB, Betting You Won't Stop Shopping Or Traveling - ARK Fintech Innovation ETF ( BATS:ARKF ) , Airbnb ( NASDAQ:ABNB ) 6/25/2025 1:52:00 AM
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? 6/19/2025 11:22:00 AM
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly ( NYSE:LLY ) , Verve Therapeutics ( NASDAQ:VERV ) 6/18/2025 5:59:00 PM
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement 6/18/2025 1:35:00 PM
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. 6/17/2025 2:07:00 PM
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease ( SCD ) at European Hematology Association ( EHA ) 2025 Congress 6/13/2025 11:00:00 AM
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? 6/11/2025 2:33:00 PM

Financial Details for BEAM

Company Overview

Ticker BEAM
Company Name Beam Therapeutics Inc
Country USA
Description Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 17.01
Price 4 Years Ago 79.69
Last Day Price Updated 6/30/2025 8:00:44 PM EST
Last Day Volume 1,531,459
Average Daily Volume 1,811,518
52-Week High 35.25
52-Week Low 13.53
Last Price to 52 Week Low 25.72%

Valuation Measures

Trailing PE N/A
Industry PE 60.05
Sector PE 40.73
5-Year Average PE -11.67
Free Cash Flow Ratio 3.24
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 32.54
Current Ratio Most Recent Quarter 8.81
Total Cash Per Share 5.25
Book Value Per Share Most Recent Quarter 11.52
Price to Book Ratio 1.50
Industry Price to Book Ratio 18.77
Sector Price to Book Ratio 30.79
Price to Sales Ratio Twelve Trailing Months 26.57
Industry Price to Sales Ratio Twelve Trailing Months 48.41
Sector Price to Sales Ratio Twelve Trailing Months 35.57
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 100,557,000
Market Capitalization 1,710,474,570
Institutional Ownership 98.07%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -184.28%
Reported EPS 12 Trailing Months -4.61
Reported EPS Past Year -1.24
Reported EPS Prior Year -4.58
Net Income Twelve Trailing Months -387,343,000
Net Income Past Year -376,742,000
Net Income Prior Year -132,527,000
Quarterly Revenue Growth YOY 0.80%
5-Year Revenue Growth 412.30%
Operating Margin Twelve Trailing Months -1,597.00%

Balance Sheet

Total Cash Most Recent Quarter 527,907,000
Total Cash Past Year 281,967,000
Total Cash Prior Year 435,895,000
Net Cash Position Most Recent Quarter 526,120,000
Net Cash Position Past Year 278,960,000
Long Term Debt Past Year 3,007,000
Long Term Debt Prior Year 3,007,000
Total Debt Most Recent Quarter 1,787,000
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 733,545,000
Total Stockholder Equity Prior Year 981,329,000
Total Stockholder Equity Most Recent Quarter 1,123,136,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -360,956,000
Free Cash Flow Per Share Twelve Trailing Months -3.59
Free Cash Flow Past Year -356,192,000
Free Cash Flow Prior Year -182,927,000

Options

Put/Call Ratio 0.05
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.22
MACD Signal -0.21
20-Day Bollinger Lower Band 10.41
20-Day Bollinger Middle Band 20.62
20-Day Bollinger Upper Band 30.83
Beta 2.08
RSI 45.63
50-Day SMA 23.92
150-Day SMA 30.32
200-Day SMA 39.46

System

Modified 6/30/2025 6:44:23 PM EST